Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit by Amanullah, Shakeel & Venkataraman, Ramesh
Available online at http://ccforum.com/content/8/6/E2 
 
Evidence-Based Medicine Journal Club  
EBM Journal Club Section Editor: Eric B. Milbrandt, MD, MPH  
 
Journal club critique 
A comparison of albumin and saline for fluid resuscitation in the 
intensive care unit   
Shakeel Amanullah
1 and Ramesh Venkataraman
2 
1 Clinical Fellow, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 
2 Assistant Professor, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 
 
Published online: 1 November 2004  
This article is online at http://ccforum.com/content/8/6/E2  
© 2004 BioMed Central Ltd 
 
 
Critical Care 2004, 8: E2 (DOI 10.1186/cc3006) 
 
 
Expanded Abstract 
Citation 
Finfer S, Bellomo R, Boyce N, et al; SAFE Study 
Investigators. A comparison of albumin and saline for fluid 
resuscitation in the intensive care unit. NEJM. 2004; 
350:2247-2256. 
Hypothesis 
When 4% albumin is compared with 0.9% sodium chloride 
(normal saline) for intravascular-fluid resuscitation in 
patients in the intensive care unit (ICU), there is no 
difference in the 28-day rate of death from any cause. 
Methods 
Design: Multicenter, double blind, randomized controlled 
trial 
Setting: Closed, multidisciplinary ICUs of 16 academic 
tertiary hospitals in Australia and New Zealand between 
November 2001 and June 2003 
Patients: 6997 ICU patients ≥ 18 years of age who were 
judged by their treating physician to require fluid 
resuscitation to maintain or increase intravascular volume, 
with this decision supported by the fulfillment of at least one 
objective criterion. Patients admitted to the ICU after cardiac 
surgery, after liver transplantation, or for the treatment of 
burns were excluded. 
Intervention: Patients were randomly assigned to receive 
either 4% albumin or normal saline, with randomization 
stratified according to institution and whether there was a 
diagnosis of trauma on admission to the ICU. Study fluids 
were supplied in identical 500-ml bottles, and blinding was 
ensured through the use of specially designed masking 
cartons and specially designed and manufactured 
administration sets. The effectiveness of the blinding was 
confirmed in a formal study before the trial was initiated. 
The treating clinicians determined the amount and rate of 
fluid administration. In addition to the study fluid, patients 
received maintenance fluids, specific replacement fluids, 
enteral or parenteral nutrition, and blood products at the 
discretion of the treating clinicians. The monitoring of central 
venous pressure, pulmonary-artery catheterization, and all 
other aspects of patient care were performed at the 
discretion of the treating clinicians.  
Outcomes: The primary endpoint was 28-day all-cause 
mortality. Secondary endpoints were the proportion of 
patients with new organ failure and the duration of 
mechanical ventilation, renal replacement therapy, and ICU 
and hospital stay.  Differences in the primary endpoint were 
also examined in six predefined subgroups according to the 
baseline presence or absence of trauma, severe sepsis, 
and acute respiratory distress syndrome (ARDS). The study 
had 90% power to detect a 3% absolute difference between 
groups for the primary endpoint. 
Results 
Of the 6997 patients who underwent randomization, 3497 
were assigned to receive albumin and 3500 to receive 
saline. Both groups had similar baseline characteristics. Of 
those who completed 28-day follow up, there were 726 
deaths (20.9%) in the albumin group, as compared with 729 
deaths (21.1%) in the saline group (relative risk of death, 
0.99; 95 percent confidence interval, 0.91 to 1.09; P=0.87). 
There were no differences in secondary endpoints between 
groups. 
A post-hoc subgroup analysis of trauma patients showed a 
trend towards increased mortality in the albumin group, 
which appeared to be due to a greater number of deaths in 
trauma patients with associated brain injury. Among patients 
who had trauma without brain injury, there was no Critical Care   December 2004 Vol 8 No 6    Amanullah and Venkataraman 
difference in mortality between the groups. In patients with 
severe sepsis there was a trend towards decreased 
mortality in the albumin group. There were no differences 
between groups in mortality for patients with ARDS. 
Conclusion 
In patients in the ICU, use of either 4% albumin or normal 
saline for fluid resuscitation resulted in similar outcomes at 
28 days. 
 
Commentary 
Albumin has been used for over 50 years for fluid 
resuscitation in the ICU, despite the lack of any adequately 
powered randomized clinical trials with mortality as a 
primary endpoint. Furthermore, two recent large meta-
analyses revealed conflicting results;
2,3 one concluded that 
albumin was associated with increased mortality whereas 
the other failed to detect this effect.  
The Saline versus Albumin Fluid Evaluation (SAFE) Study 
addressed one of the most pressing questions faced by 
intensivists.  The data showed that there is no advantage to 
resuscitation with albumin as compared to normal saline. 
This study has several strengths worth mentioning. First, the 
investigators went to great lengths to ensure blinding. 
Albumin is yellow and tends to foam during administration, 
making it very easy to distinguish from saline. Specially 
designed masking cartons and administration sets were 
used to prevent unblinding and the effectiveness of these 
measures was ensured by a formal study prior to the trial. 
Second, this study enrolled a very large number of patients 
in a relatively small period of time, which was facilitated by 
the use of delayed consent provision. Such an approach 
would not have been possible had this trial been conducted 
in the United States. Third, compliance was outstanding and 
contamination was negligible, an exceptional achievement 
considering the size and scope of the trial.  
A few limitations deserve consideration. First, the study 
hypothesis suggests that this was an equivalence trial. 
However, the study was powered to detect a 3% difference 
in 28-day morality. The absence of a detectable difference 
suggests equivalence, but proof of equivalence would 
require a different sample size. Second, during the first four 
days, patients in the albumin group received 71.0 mL more 
packed red cells than those assigned to receive normal 
saline. Given the recent concern that blood transfusion may 
be associated with worse outcomes, it is possible the 
additional, albeit small, volume of packed red blood cells 
received biased the results in favor of normal saline. Third, 
despite extensive measures taken to ensure blinding, 
clinicians were able to obtain serum albumin levels. It is 
conceivable that a rising serum albumin concentration 
would be indicative of randomization to the albumin group. 
However, the differences in mean daily serum albumin 
levels between groups were quite small and it seems 
unlikely that clinicians would have be successful in using 
this measure to guess treatment assignment.  
 
Recommendation 
Based on the results of this study, we conclude that the 
routine use of albumin for fluid resuscitation of critically ill 
patients is not warranted.  Albumin solutions for 
resuscitation may still be warranted in certain highly 
selected patient populations, such as liver transplant 
patients and those with burns. Whether albumin or normal 
saline confers benefit in other selected patient populations, 
such as those with traumatic brain injury or sepsis, requires 
further study.  
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